Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 15;15(5):886-897.
doi: 10.4239/wjd.v15.i5.886.

Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study

Affiliations

Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study

Joseph Matthew Gosnell et al. World J Diabetes. .

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are a growing health burden across a significant portion of the global patient population. However, these conditions seem to have disparate rates and outcomes between different ethnic populations. The combination of MASLD/MASH and type 2 diabetes increases the risk of hepatocellular carcinoma (HCC), and Hispanic patients experience the greatest burden, particularly those in South Texas.

Aim: To compare outcomes between Hispanic and non-Hispanic patients in the United States, while further focusing on the Hispanic population within Southeast Texas to determine whether the documented disparity in outcomes is a function of geographical circumstance or if there is a more widespread reason that all clinicians must account for in prognostic consideration.

Methods: This cohort analysis was conducted with data obtained from TriNetX, LLC ("TriNetX"), a global federated health research network that provides access to deidentified medical records from healthcare organizations worldwide. Two cohort networks were used: University of Texas Medical Branch (UTMB) hospital and the United States national database collective to determine whether disparities were related to geographic regions, like Southeast Texas.

Results: This study findings revealed Hispanics/Latinos have a statistically significant higher occurrence of HCC, type 2 diabetes mellitus, and liver fibrosis/cirrhosis in both the United States and the UTMB Hispanic/Latino groups. All-cause mortality in Hispanics/Latinos was lower within the United States group and not statistically elevated in the UTMB cohort.

Conclusion: This would appear to support that Hispanic patients in Southeast Texas are not uniquely affected compared to the national Hispanic population.

Keywords: Diabetes mellitus; Hepatocellular carcinoma; Hispanic; Metabolic dysfunction-associated steatohepatitis; Metabolic dysfunction-associated steatotic liver disease; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Steatotic liver disease; TriNetX.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Figures

Figure 1
Figure 1
Histological appearance of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis at 100 × magnification (hematoxylin and eosin stain). A: A non-alcoholic fatty liver diseases activity score (NAS) 3/8; B: A NAS 6/8 which constitutes a moderate-severe steatohepatitis. Blue triangles denote macrovesicular steatosis. Black stars denote ballooned hepatocytes. Black bars in lower right corner denote scale bar of 50 μm.
Figure 2
Figure 2
Patient demographic flow chart. The chart demonstrates the total number of metabolic dysfunction-associated steatohepatitis patients in both United States and University of Texas Medical Branch cohorts, total number of Hispanic/Latino and non-Hispanic/Latino patients in each cohort, the effects of Propensity Score Matching on cohort size, and the total number of male and female patients in each sub-cohort. MASH: Metabolic dysfunction-associated steatohepatitis; UTMB: University of Texas Medical Branch; HCO: Healthcare organizations.
Figure 3
Figure 3
Kaplan-Meier survival analysis curves for United States and University of Texas Medical Branch cohorts. Hispanic/Latino patients are represented in red, while non-Hispanic/Latino patients are represented in blue. The four primary outcomes (all-cause mortality, hepatocellular carcinoma, type 2 diabetes mellitus, and fibrosis/cirrhosis of the liver) are represented for both cohorts. MASH: Metabolic dysfunction-associated steatohepatitis; UTMB: University of Texas Medical Branch; HCC: Hepatocellular carcinoma; T2DM: Type 2 diabetes mellitus.

Similar articles

References

    1. Stepanova M, Kabbara K, Mohess D, Verma M, Roche-Green A, AlQahtani S, Ong J, Burra P, Younossi ZM. Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients. Hepatol Commun. 2022;6:1506–1515. - PMC - PubMed
    1. Wang S, Toy M, Hang Pham TT, So S. Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019. PLoS One. 2020;15:e0239393. - PMC - PubMed
    1. Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018;113:1649–1659. - PMC - PubMed
    1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–1835. - PMC - PubMed
    1. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80:e54–e56. - PubMed